{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:16:20Z","timestamp":1765545380749,"version":"3.32.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T00:00:00Z","timestamp":1145923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H<jats:sub>3<\/jats:sub>\u2010receptor ligands on neuroleptic\u2010induced catalepsy, apomorphine\u2010induced climbing behavior and amphetamine\u2010induced locomotor activities in mice. Catalepsy was induced by haloperidol (2\u2003mg\/kg p.o.), while apomorphine (1.5\u2003mg\/kg s.c.) and amphetamine (2\u2003mg\/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (<jats:italic>R<\/jats:italic>)\u2010<jats:italic>\u03b1<\/jats:italic>\u2010methylhistamine (RAMH) (5\u2003<jats:italic>\u03bc<\/jats:italic>g i.c.v.) and thioperamide (THP) (15\u2003mg\/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15\u2003mg\/kg i.p.) 1\u2003h prior to haloperidol resulted in a dose\u2010dependent increase in the catalepsy times (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15\u2003mg\/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15\u2003mg\/kg i.p.) per se had no effect on these parameters. On amphetamine\u2010induced hyperactivity, THP (3.75 and 7.5\u2003mg\/kg i.p.) reduced locomotor time, distance traveled and average speed (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Pretreatment with RAMH (5\u2003<jats:italic>\u03bc<\/jats:italic>g i.c.v.) could partially reverse such effects of THP (3.75\u2003mg\/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic\u2010like profile by potentiating haloperidol\u2010induced catalepsy, reducing amphetamine\u2010induced hyperactivity and reducing apomorphine\u2010induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H<jats:sub>3<\/jats:sub>\u2010receptors. Findings suggest a potential for H<jats:sub>3<\/jats:sub>\u2010receptor antagonists in improving the refractory cases of schizophrenia.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2006.00411.x","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T17:52:51Z","timestamp":1145987571000},"page":"373-378","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antipsychotic\u2010like profile of thioperamide, a selective H<sub>3<\/sub>\u2010receptor antagonist in mice"],"prefix":"10.1111","volume":"20","author":[{"given":"Mohd","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Uma Devi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Vohora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-16-07272.2002"},{"key":"e_1_2_6_3_2","first-page":"416","volume-title":"Neuro\u2010regulators and psychiatric disorders","author":"Rauscher F.P.","year":"1977"},{"key":"e_1_2_6_4_2","first-page":"44","article-title":"Histamine and schizophrenia","volume":"41","author":"Rauscher F.P.","year":"1980","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00215-7"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(94)00034-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890150306"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(91)90290-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02247479"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb14934.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00379-5"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00474-9"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359459"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00292-S"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(78)90251-0"},{"key":"e_1_2_6_16_2","first-page":"667","article-title":"Selective histamine H3\u2010receptor ligands and cognitive functions: an overview","volume":"7","author":"Vohora D.","year":"2004","journal-title":"Investig. Drugs"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(94)00146-J"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(02)01030-4"},{"key":"e_1_2_6_19_2","first-page":"545","article-title":"The behavioral pharmacology of olanzapine, a novel \u2018atypical\u2019 antipsychotic agent","volume":"262","author":"Moore N.A.","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0022-3565(24)37994-7","article-title":"Atypical neuroleptics enhance histamine turnover in brain via 5\u2010hydroxytryptamine 2A receptor blockade","volume":"288","author":"Morisset S.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_21_2","first-page":"295","article-title":"Brain histamine and neuroleptic\u2010induced catalepsy","volume":"21","author":"Yagi A.","year":"1990","journal-title":"Ann. Rep. Pharmacopsychol. Res. Found."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1982.tb04673.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/327117a0"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.03.018"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.14.030191.002225"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(95)00057-7"},{"key":"e_1_2_6_27_2","first-page":"116S","article-title":"Adjunctive fluoxetine in haloperidol \u2013 stabilized schizophrenics","volume":"9","author":"Ames D.","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470070109"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.1_Part_1.211"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.5.836b"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01250091"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90498-7"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(84)90055-7"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244933"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_140.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050882"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2006.00411.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2006.00411.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:18:52Z","timestamp":1736356732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2006.00411.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1472-8206.2006.00411.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2006.00411.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"type":"print","value":"0767-3981"},{"type":"electronic","value":"1472-8206"}],"subject":[],"published":{"date-parts":[[2006,4,25]]},"assertion":[{"value":"2006-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}